IDiyas

For the Inventor, By the Inventor

Rahway, NJ, United States of America

Frederick M Kahan

USPTO Granted Patents = 19

Average Co-Inventor Count = 2.4

ph-index = 5

Forward Citations = 198(Granted Patents)


Location History:

  • Rahway, NJ (US) (1976 - 1981)
  • Scotch Plains, NJ (US) (1985 - 1992)

Company Filing History:

goldMedal19 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1992

Loading Chart...
19 patents (USPTO):Explore Patents
1. 5147868 - Thienamycin renal peptidase inhibitors (1992-09-15),
2. 5071843 - Combination of 2-substituted carbapenems with dipeptidase inhibitors (1991-12-10),
3. 4880793 - Combination of thienamycin-type antibiotics with dipeptidase inhibitors (1989-11-14),
4. 4668504 - Use of substituted propenoates to prevent nephrotoxicity of certain (1987-05-26),
5. 4616038 - Combination of thienamycin-type antibiotics with dipeptidase inhibitors (1986-10-07),
6. 4539208 - Combination of thienamycin-type antibiotics with dipeptidase inhibitors (1985-09-03),
7. 4304867 - Culture of Streptomyces cattleya (1981-12-08),
8. 4282322 - Process for enzymatic deacylation of antibiotics (1981-08-04),
9. 4264734 - Process for producing antibiotic desacetyl 890A.sub.10 (1981-04-28),
10. 4229534 - Acetylthienamycin production (1980-10-21),
11. 4165379 - N-acetyl thienamycin (1979-08-21),
12. 4162193 - Enzymatic cleavage of N-acyl-thienamycins (1979-07-24),
13. 4135978 - Production of N-acyl-thienamycins (1979-01-23),
14. 4081548 - Antibiotics (1978-03-28),
15. 4031231 - Antibacterial composition comprising 3-fluoro-D-alanine or deutero (1977-06-21),

Title: Frederick M. Kahan: A Pioneer in Pharmaceutical Innovations

Introduction

Frederick M. Kahan, based in Rahway, NJ, is a distinguished inventor with a remarkable portfolio of 19 patents. His contributions to the field of pharmaceuticals have had a significant impact, particularly in the development of innovative compounds that enhance the efficacy of antibacterial products.

Latest Patents

Among his latest inventions, Kahan has developed novel chemical compounds that act as Thienamycin renal peptidase inhibitors. These compounds selectively inhibit the metabolism of dipeptidase (E.C.3.4.13.11), making them valuable in combination with antibacterial products. Specifically, these chemical compounds are z-2-acylamino-3-monosubstituted propenoates. Additionally, he has disclosed a formulation that combines 2-substituted carbapenems with dipeptidase inhibitors, showcasing his innovative approach to enhancing pharmaceutical performance.

Career Highlights

Frederick M. Kahan works with Merck & Company, Inc., a leading global health care company, known for its commitment to improving health through drug innovation. His work and inventions have helped shape the landscape of modern medicine, particularly in antibiotic development.

Collaborations

Throughout his career, Kahan has collaborated with talented colleagues such as Jean S. Kahan and Robert T. Goegelman. These collaborations have fostered a creative environment that promotes pioneering research and the development of groundbreaking pharmaceutical solutions.

Conclusion

Frederick M. Kahan stands out as a prominent figure in the realm of pharmaceutical innovations. With a strong track record of patents and successful collaborations, he continues to contribute to the advancement of healthcare solutions, making a difference in the lives of many. His work exemplifies the value of innovation in addressing critical medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…